Results 51 to 60 of about 204,699 (375)

TGF-β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

International Journal of Molecular Medicine, 2021
Idiopathic pulmonary fibrosis (IPF) is a worldwide disease characterized by the chronic and irreversible decline of lung function. Currently, there is no drug to successfully treat the disease except for lung transplantation.
Zhimin Ye, Yongbin Hu
semanticscholar   +1 more source

Imaging diagnosis-computed tomography of traction bronchiectasis secondary to pulmonary fibrosis in a Patterdale Terrier [PDF]

, 2016
An 8-year-old, Patterdale terrier was referred for evaluation of tachypnoea, exercise intolerance, and weight loss. Computed tomographic images showed pneumomediastinum, diffuse pulmonary ground glass opacity, and marked dilatation of peripheral bronchi,
Fitzgerald, E, Lamb, C R, Priestnall, S L   +2 more
core   +2 more sources

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

New England Journal of Medicine, 2014
BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations
L. Richeldi, R. D. du Bois, G. Raghu, A. Azuma, K. Brown, U. Costabel, V. Cottin, K. Flaherty, D. Hansell, Y. Inoue, D. S. Kim, M. Kolb, A. Nicholson, P. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard, S. Stowasser, R. Schlenker‐Herceg, B. Disse, H. Collard   +22 more
semanticscholar   +1 more source

Management of Idiopathic Pulmonary Fibrosis [PDF]

Clinics in Chest Medicine, 2012
Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls.
CERRI, Stefania, SPAGNOLO, Paolo, F. Luppi, RICHELDI, Luca   +3 more
openaire   +6 more sources

Spatial and temporal variability of idiopathic pulmonary fibrosis cases in Silesian Voivodeship in years 2006–2010

International Journal of Occupational Medicine and Environmental Health, 2017
Objectives: Idiopathic pulmonary fibrosis (IPF) (J84.1 by the International Statistical Classification of Diseases and Related Health Problems, 10th revision – ICD-10) is a rare disease of unknown cause.
Ewa Niewiadomska, Małgorzata Kowalska, Jan E. Zejda   +2 more
doaj   +1 more source

TGF-beta 1 induces human alveolar epithelial to mesenchymal cell transition (EMT) [PDF]

, 2005
Background: Fibroblastic foci are characteristic features in lung parenchyma of patients with idiopathic pulmonary fibrosis (IPF). They comprise aggregates of mesenchymal cells which underlie sites of unresolved epithelial injury and are associated with ...
A Atfi, A Desmouliere, A Desmouliere, CM Ewing, D Upadhyay, DA Vesey, DG. Hoyt, DW Powell, DW Powell, DY Rhyu, E Healy, E Piek, EE Moussad, EP Bottinger, F Strutz, G Raghu, GR Grotendorst, HW Yao, J Fan, J Gauldie, J Nightingale, J Yang, JT Allen, JT Allen, K Vleminckx, KA Foster, LH Pan, M Kelly, M Selman, M Selman, M Whitman, N Khalil, N Khalil, N Khalil, NA Bhowmick, NA Wahab, NA Wahab, NA Wahab, P Bonniaud, P Sharmila, PJ Miettinen, PJ Sime, R Derynck, R Kalluri, S Hashimoto, T Maeyama, TE King Jr, TJ Gross, V Mermall, Y Higashimoto, Y Liu   +50 more
core   +4 more sources

Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis [PDF]

, 2012
Extracellular matrix deposition and tissue scarring characterize the process of fibrosis. Transforming growth factor beta (TGFβ) and Insulin-like growth factor binding protein-3 (IGFBP-3) have been implicated in the pathogenesis of fibrosis in various ...
Adriana T. Larregina, Carol A. Feghali-Bostwick, Joseph M. Pilewski, Logan R. Mlakar, Sebastien Fuchs, Ximena D. Ruiz, Yukie Yamaguchi, Yunyun Su   +7 more
core   +11 more sources

Pulmonary fibrosis: “idiopathic” is not “cryptogenic” [PDF]

European Respiratory Journal, 2019
The additional argument advanced by Professor Cottin for retention of the term “idiopathic pulmonary fibrosis” is highly persuasivehttp://ow.ly ...
Wells, Athol U, Brown, Kevin K, Flaherty, Kevin R, Kolb, Martin, Thannickal, Victor J, Vancheri C   +5 more
openaire   +3 more sources

Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis

Revista Portuguesa de Pneumologia (English Edition), 2016
Idiopathic pulmonary fibrosis is a rare interstitial lung disease included in the Idiopathic Interstitial Pneumonias group. Although several potential risk factors have been described, it is a progressive fibrosing disease of unknown cause affecting ...
C. Robalo Cordeiro, P. Campos, L. Carvalho, S. Campainha, S. Clemente, L. Figueiredo, J.M. Jesus, A. Marques, C. Souto-Moura, R. Pinto Basto, A. Ribeiro, M. Serrado, A. Morais   +12 more
doaj   +1 more source

Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management

Respiratory Research, 2021
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly subjects, and epidemiological studies suggest that the main risk ...
F. Luppi, M. Kalluri, P. Faverio, M. Kreuter, G. Ferrara   +4 more
semanticscholar   +1 more source